<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121744</url>
  </required_header>
  <id_info>
    <org_study_id>SC001:V.1.0:Dated 12/12/2008.</org_study_id>
    <nct_id>NCT01121744</nct_id>
  </id_info>
  <brief_title>Supralimus-Core™ Pharmacokinetic (PK) Study</brief_title>
  <official_title>Supralimus-Core™ Pharmacokinetic (PK) Study: Evaluation of Pharmacokinetic (PK) and Safety of the Supralimus-Core™ Sirolimus Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahajanand Medical Technologies Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahajanand Medical Technologies Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetic (PK) and safety&#xD;
      associated with Supralimus-Core™ Sirolimus Eluting Coronary Stent system in the treatment of&#xD;
      single de novo lesions in native coronary arteries between 2.5 to 3.5 mm in diameter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centric, interventional, non-randomized, open label, Uncontrolled, single&#xD;
      group assignment, Pharmacokinetics study. Approximately 20 patients will be enrolled in the&#xD;
      study. Patients will be followed for 48 days post-procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax, Tmax, AUC24h, AUClast, AUC∞, λz, t½term, CL</measure>
    <time_frame>Up to 48 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>Up to 48 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Supralimus-Core™ Sirolimus eluting Coronary Stent</intervention_name>
    <description>Supralimus-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Sirolimus Drug concentration is 1.4 µg/mm2.</description>
    <other_name>Drug Eluting Stent (DES)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients with de novo native coronary artery lesions located in epicardial vessel who&#xD;
        qualify for percutaneous coronary intervention will be included according to the inclusion&#xD;
        and exclusion criteria specified below:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. Eligible for percutaneous coronary intervention (PCI)&#xD;
&#xD;
          3. Acceptable candidate for CABG&#xD;
&#xD;
          4. Clinical evidence of ischemic heart disease and/or a positive territorial functional&#xD;
             study. Documented stable angina pectoris ((Canadian Cardiovascular Society (CCS)&#xD;
             Classification 1, 2, 3 or 4) or unstable angina pectoris with documented ischemia&#xD;
             (Braunwald Class IB-C, IIB-C or IIIB-C), or documented silent ischemia.&#xD;
&#xD;
          5. The target lesion is a single de novo coronary artery lesion with ≥ 50% and &lt; 100%&#xD;
             stenosis in one of the major epicardial territories (LAD, LCX or RCA). A second target&#xD;
             lesion in another major epicardial vessel could be treated and this second lesion&#xD;
             should fit with the inclusion/exclusion criteria and will receive the same type of&#xD;
             stent.&#xD;
&#xD;
          6. The target lesion must be covered by one study stent, preferably with a margin of 3 mm&#xD;
             on each side of the lesion.&#xD;
&#xD;
          7. The target lesion must be ≤ 34 mm in length by visual estimate.&#xD;
&#xD;
          8. The target reference vessel diameter must be ≥ 2.5 mm and ≤ 3.5 mm.&#xD;
&#xD;
          9. Patient or patient's legal representative has been informed of the nature of the study&#xD;
             and agrees to its provisions and has provided written informed consent as notified /&#xD;
             approved by the Institutional Review Board/Ethics Committee of the clinical site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female of childbearing potential&#xD;
&#xD;
          2. Documented left ventricular ejection fraction (LVEF) ≤ 25%&#xD;
&#xD;
          3. Evidence of an acute Q-wave or non-Q-wave myocardial infarction within 72 hours&#xD;
             preceding the index procedure&#xD;
&#xD;
          4. Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®, Ceruvin) or&#xD;
             ticlopidine (Ticlid®), heparin, sirolimus, cobalt chromium, contrast agent (that&#xD;
             cannot be adequately pre-medicated)&#xD;
&#xD;
          5. A platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3 or a WBC &lt;3,000 cells/mm3&#xD;
&#xD;
          6. Acute or chronic renal dysfunction (creatinine &gt;2.0mg/dl or &gt;150µmol/L)&#xD;
&#xD;
          7. Target vessel has evidence of thrombus&#xD;
&#xD;
          8. Target vessel is excessively tortuous which makes it unsuitable for proper stent&#xD;
             delivery and deployment&#xD;
&#xD;
          9. Previous bare metal stenting (less than 1 year) anywhere within the target vessel&#xD;
&#xD;
         10. Previous drug-eluting stenting anywhere within any epicardial vessel&#xD;
&#xD;
         11. The target lesion requires treatment with a device other than PTCA prior to stent&#xD;
             placement (e.g. but not limited to, directional coronary atherectomy, excimer laser,&#xD;
             rotational atherectomy, etc.)&#xD;
&#xD;
         12. Significant (&gt;50%) stenosis proximal or distal to the target lesion that might require&#xD;
             revascularization or impede run-off&#xD;
&#xD;
         13. Heavily calcified lesion and/or calcified lesion which cannot be successfully&#xD;
             predilated&#xD;
&#xD;
         14. Target lesion is located in or supplied by an arterial or venous bypass graft&#xD;
&#xD;
         15. Ostial target lesion&#xD;
&#xD;
         16. Patient is currently participating in an investigational drug or device study,&#xD;
             including its follow-up period&#xD;
&#xD;
         17. Within 30 days prior to procedure, patient has undergone a previous coronary&#xD;
             interventional procedure of any kind&#xD;
&#xD;
         18. Within 48 days post-procedure, patient requires planned interventional treatment of&#xD;
             any non-target vessel. Planned intervention of the target vessel after the index&#xD;
             procedure is not allowed.&#xD;
&#xD;
         19. CVA within previous 6 months&#xD;
&#xD;
         20. Unprotected Left Main (LM) coronary artery disease (stenosis &gt;50%)&#xD;
&#xD;
         21. In the investigator's opinion, patient has a co-morbid condition(s) that could limit&#xD;
             the patient's ability to participate in the study, compliance with follow-up&#xD;
             requirements or impact the scientific integrity of the study&#xD;
&#xD;
         22. Planned surgery within 48 days after the index procedure&#xD;
&#xD;
         23. Life expectancy less than 1 year&#xD;
&#xD;
         24. Any contraindication to blood sampling&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Life Care Institute of Medical Science &amp; research</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baroda Heart Institute &amp; Research Center</name>
      <address>
        <city>Baroda</city>
        <state>Gujarat</state>
        <zip>390007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shree B. D. Mahavir Heart Institute</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>395001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bankers Heart Institute</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Thakkar AS, Abhyankar AD, Dani SI, Banker DN, Singh PI, Parmar SA, Mehta AA. Systemic exposure of sirolimus after coronary stent implantation in patients with de novo coronary lesions: Supralimus-Core® pharmacokinetic study. Indian Heart J. 2012 May-Jun;64(3):273-9. doi: 10.1016/S0019-4832(12)60086-8.</citation>
    <PMID>22664810</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <last_update_submitted>July 3, 2012</last_update_submitted>
  <last_update_submitted_qc>July 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dr. Atul Abhyankar</name_title>
    <organization>Sahajanand Medical Technologies Pvt. Ltd.</organization>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Drug Eluting Stents (DES)</keyword>
  <keyword>Pharmacokinetic (PK)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

